Source: Annual Congress 2003 - Management of tuberculosis and tubercular infection - old and new considerations
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
R. L. Cowie, H. Bent (Calgary, Canada). Treatment of latent tuberculosis infection: completion rates and adverse effects. Eur Respir J 2003; 22: Suppl. 45, 3303

Member's Comments

No comment yet.

Related content which might interest you: Adverse events during treatment for latent tuberculosis infection Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Effect of time since seroconversion to HIV: rates and risks of recurrent tuberculosis Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008 Completion of treatment for latent tuberculosis infection Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016 Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006 Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report Source: Eur Respir J, 54 (6) 1901522; 10.1183/13993003.01522-2019 Year: 2019 Risk of serious adverse reactions during the treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Treatment of latent infection with Mycobacterium tuberculosis: update 2010 Source: Eur Respir J 2011; 37: 690-711 Year: 2011 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 Patient choice promotes adherence in preventive treatment for latent tuberculosis Source: Eur Respir J 2007; 30: 728-735 Year: 2007 Factors associated with completion of tuberculosis treatment Source: Eur Respir J 2005; 26: Suppl. 49, 428s Year: 2005 Treatment failure in tuberculosis Source: Eur Respir J 2007; 29: 561-564 Year: 2007 The influence of SARS-CoV-2 co-infection and active tuberculosis on the severity of the disease course and mortality. Source: Virtual Congress 2021 – Tuberculosis, COVID-19 and other comorbidities Year: 2021 Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban Year: 2008 Adverse effects among MDR/XDR TB patients with viral hepatitus appearing during TB chemotherapy Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Diagnosis and treatment of latent tuberculosis infection Source: Eur Respir Monogr 2018; 82: 381-398 Year: 2018 Features of development of TB infection caused by different doses of MBT Source: International Congress 2018 – The immune response to tuberculosis: development of biomarkers and diagnostic tools Year: 2018